325 related articles for article (PubMed ID: 16871769)
1. [Biological treatment of rheumatic diseases].
Procházková L; Böhmová J; Soucek M
Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
[TBL] [Abstract][Full Text] [Related]
2. Anti-cytokine antibodies for rheumatic diseases.
Atzeni F; Sarzi-Puttini P
Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
[TBL] [Abstract][Full Text] [Related]
3. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
Mariette X
Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
[No Abstract] [Full Text] [Related]
4. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
5. mAbs in nonlupus autoimmune rheumatic disease.
Whelan BR; Isenberg DA
Curr Opin Hematol; 2009 Jul; 16(4):280-4. PubMed ID: 19444098
[TBL] [Abstract][Full Text] [Related]
6. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
7. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects.
Setty AR; Sigal LH
Semin Arthritis Rheum; 2005 Jun; 34(6):773-84. PubMed ID: 15942912
[TBL] [Abstract][Full Text] [Related]
8. Rheumatoid vasculitis treated with infliximab.
van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC
J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of B cells for rheumatic autoimmune diseases.
Engel P; Gómez-Puerta JA; Ramos-Casals M; Lozano F; Bosch X
Pharmacol Rev; 2011 Mar; 63(1):127-56. PubMed ID: 21245206
[TBL] [Abstract][Full Text] [Related]
10. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
11. [Biological treatment of rhematoid diseases].
Pavelka K
Vnitr Lek; 2006 Jun; 52(6):561-2. PubMed ID: 16871758
[No Abstract] [Full Text] [Related]
12. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
Morović-Vergles J
Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
[TBL] [Abstract][Full Text] [Related]
13. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
Yelin E; Katz P
Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
[No Abstract] [Full Text] [Related]
14. Anti-tumour necrosis factor agents and lipid profile: a class effect?
Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
[No Abstract] [Full Text] [Related]
15. Mycobacterial disease in patients with rheumatic disease.
van Ingen J; Boeree MJ; Dekhuijzen PN; van Soolingen D
Nat Clin Pract Rheumatol; 2008 Dec; 4(12):649-56. PubMed ID: 19037226
[TBL] [Abstract][Full Text] [Related]
16. TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - an evidence based approach.
Winterhalter S; Niehues T
Klin Padiatr; 2008; 220(6):342-7. PubMed ID: 18949668
[TBL] [Abstract][Full Text] [Related]
17. [Pregnancy in rheumatic patients treated with biologic drugs].
Sentić M; Baresić M; Anić B; Bosnić D; Cerovec M; Mayer M; Smiljanić L; Cikes N
Lijec Vjesn; 2010; 132(9-10):317-8. PubMed ID: 21261033
[No Abstract] [Full Text] [Related]
18. [Non-TNF biologicals in therapy].
Wollenhaupt J; Burmester GR
Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
[No Abstract] [Full Text] [Related]
19. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
Haraoui B
J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
[No Abstract] [Full Text] [Related]
20. New cytokine targets in inflammatory rheumatic diseases.
Connell L; McInnes IB
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):865-78. PubMed ID: 16980211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
